Behavioral Health Business August 15, 2024
Late last week, the psychedelics industry received its latest blow when the FDA shot down Lykos Therapeutics’ application for MDMA-assisted therapy for treating PTSD.
Many in the psychedelics industry had hailed Lykos Therapeutics’ treatment as the pioneer for regulatory clearance. However, the FDA sent the pharma company back to the drawing board for more testing, requesting additional Phase 3 trial research to prove the therapy’s safety and efficacy.
This setback has raised some questions about the use and feasibility of psychedelics and other experimental treatments in traditional mental health settings.
It has also put a pin in the idea that psychedelics and other experimental treatments could be the silver bullet for mental health treatments in the future.
In recent years,...
Today's Sponsors
Today's Sponsor